Table 3. Eligible hemostatic agents and therapies for congenital/acquired bleeding disorders.
| Therapy Class | Hemostatic Agent |
|---|---|
| Prothrombin Complex Concentrate (PCC) | 3-factor PCC (e.g. Bebulin®) |
| 4-factor PCC (e.g. Octaplex®) | |
| Activated Prothrombin Complex Concentrate (aPCC) | aPCC (e.g. FEIBA®) |
| Recombinant Factor VIIa (rFVIIa) | rFVIIa (e.g. Novoseven®, Sevenfact®) |
| Fresh Frozen Plasma (FFP) | --- |
| Andexanet Alfa (Andexxa®/Ondexxya®) | --- |
| Idarucizumab (Praxbind®) | --- |
| Ciraparantag (aripazine) | --- |
| Antifibrinolytics | Tranexamic Acid Aminocaproic Acid |
| Fibrinogen Concentrates | RiaSTAP |
| Fibryga | |
| Clottafact® | |
| Factor VII Concentrates | Pd-FVII |
| Factor VIII Products | Advate |
| Hemofil M | |
| Kogenate FS | |
| Koate | |
| Kovaltry | |
| Novoeight | |
| Nuwiq | |
| Recombinate | |
| Xyntha | |
| Adynovate | |
| Afstyla | |
| Eloctate | |
| Esperoct | |
| Jivi | |
| Factane | |
| Octanate | |
| Efanesoctocog alfa (Altuviiio®) | |
| Recombinant Porcine Sequence Factor VIII Concentrate | Obizur |
| Factor IX Products | AlphaNine SD |
| BeneFIX | |
| Ixinity | |
| Mononine | |
| Rixubis | |
| Alprolix | |
| Idelvion | |
| Rebinyn | |
| Factor X Products | Coagadex |
| Factor XI Products | Pd-FXI |
| Hemoleven® | |
| Factor XIII Products | Corifact |
| Tretten | |
| Bispecific Monoclonal Antibody | Emicizumab (ACE910; Hemlibra®) |
| Anti-TFPI agents | Concizumab |
| Marstacimab | |
| RNA Interference Therapy | Fitusiran |
| Aptamers | BT200 |
| Von Willebrand Concentrates | Humate-P |
| Alphanate | |
| Wilate | |
| Voncento | |
| Recombinant VWF | Vonvendi |